GENE ONLINE|News &
Opinion
Blog

China
China’s InxMed Raises $50 Million to Inhibit Cancer-Resisting FAKs
2022-03-07
Helsinn Group Gains Marketing Rights to BridgeBio’s Truseltiq in the US
2022-03-04
Sanofi Bets $2.5 billion on Adagene to Make Antibodies Safer
2022-03-03
China Pushes for Faster Approval for Gene-Edited Crops
2022-02-15
China Gives Conditional Approval to Pfizer’s Covid-19 Oral Antiviral
2022-02-14
GSK’s Benlysta Bags Approval for Lupus Nephritis Treatment in China
2022-02-14
EdiGene Digs Into Cell Therapies with Arbor and Neukio Partnerships
2022-02-10
China’s CANbridge Reports Positive Phase 1 Data of Contender to AstraZeneca’s Complement Inhibitor
2022-02-08
Left, or Right? Orientation of Nanoparticles Influences Immune Response and Maturation
2022-01-25
Biotech Showcase 2022: The China Factor
2022-01-24
APAC CRO Novotech Mulls IPO after $255 Million Round
2022-01-20
GeneOnline’s Top 10 Hong Kong Biotech IPOs of 2021
2022-01-07
RNAi Player Sirnaomics Squeezes in $50 Million IPO in Hong Kong
2022-01-03
China’s Hansoh Teams Up with Middle East Onco-Collaborator
2022-01-02
CStone Wins Hong Kong Approval for Gastrointestinal Tumor Drug
2021-12-29
1 2 3 4 7
LATEST
Vaccine Protecting Against 20 Different Pneumococcal Infections Proves Effective in Trial
2022-08-12
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Extreme Climate Change Is Aggravating Infectious Diseases!
2022-08-11
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition
2022-08-11
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
RESI Boston
Boston
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!